Barclays
PGEN icon

Barclays’s Precigen PGEN Stock Holding History

Barclays’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,200
Closed -$18K – 6388
2019
Q4 		$18K Hold
3,200
– – ﹤0.01% 6002
2019
Q3 		$18K Buy
3,200
+1,000
+45% +$6.79K ﹤0.01% 6240
2019
Q2 		$17K Buy
2,200
+1,100
+100% +$5.92K ﹤0.01% 6447
2019
Q1 		$6K Sell
1,100
-159,200
-99% -$1.1M ﹤0.01% 6676
2018
Q4 		$1.05M Buy
160,300
+157,600
+5,837% +$1.77M ﹤0.01% 3064
2018
Q3 		$46K Sell
2,700
-5,700
-68% -$84.8K ﹤0.01% 6129
2018
Q2 		$117K Sell
8,400
-1,700
-17% -$28.7K ﹤0.01% 5137
2018
Q1 		$155K Buy
10,100
+2,600
+35% +$37.2K ﹤0.01% 5053
2017
Q4 		$86K Buy
7,500
+7,000
+1,400% +$104K ﹤0.01% 5359
2017
Q3 		$10K Hold
500
– – ﹤0.01% 6126
2017
Q2 		$12K Hold
500
– – ﹤0.01% 5994
2017
Q1 		$10K Sell
500
-5
-1% -$112 ﹤0.01% 6084
2016
Q4 		$12K Buy
+505
New +$14.1K ﹤0.01% 5834
2015
Q4 		– Sell
-9,686
Closed -$298K – 6430
2015
Q3 		$298K Buy
+9,686
New +$473K ﹤0.01% 3806

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Barclays's PGEN Position: Q1 2026 in Review

Barclays reduced its Precigen (PGEN) stake by 43% in Q1 2026, selling an estimated $1.53M and leaving 491,696 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

Barclays first reported a position in PGEN in Q3 2013 and has held it in 43 quarters since. The position peaked at $14.5M in Q3 2018. 205 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

  • Barclays held 491,696 shares of Precigen worth $1.9M as of Q1 2026.
  • Barclays sold 373,682 Precigen shares in Q1 2026, an estimated $1.53M.
  • Precigen made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2382 holding.
  • Barclays first reported a position in Precigen in Q3 2013 and has held it in 43 quarters since.
  • Barclays's Precigen position peaked at $14.5M in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.